Tag: Tedopi
OSE Immunotherapeutics Receives First Grant of Patent for Use of Tedopi® After Failure of PD-1 or PD-L1 Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients – 25 /01/2022 at 6:30 PM
A grant agreement issued by the Japanese Patent Office This new patent will protect Tedopi® until 2037 Nantes, France – January 25, 2022, 6:30 p.m. – OSE Immunotherapeutics SA (ISIN:…